United Therapeutics Corp., of Silver Spring, Md., reported that for the three months ended June 30, net revenues totaled $444 million. Sales of its pulmonary arterial hypertension drug, Remodulin (treprostinil injected), increased by $1.8 million over the 2017 period to $158.5 million.